Three RNA Vaccine Formats and the Lipid Problem Underneath Them
Preprint
- 9 November 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Six years after the first licensed mRNA vaccine, the argument in the field is no longer whether RNA can be delivered. It is which RNA, for how long, and at what cost in reactogenicity. Three molecular formats carry most of the work now: nucleoside-modified linear mRNA, self-amplifying RNA (saRNA) and circular RNA (circRNA). Each has produced human or near-human data since 2021, and each is limited at a different step-cytosolic lifetime, innate sensing of replication intermediates, and manufacturing. Beneath all three sits the ionizable lipid, whose discovery process has itself been redesigned: combinatorial libraries, machine learning and iterative chemical evolution have compressed what once took years into months, without yet producing a molecule that separates potency from inflammation. This Review follows the three formats through their mechanistic constraints and their clinical readouts, then examines what the lipid literature of the past five years does and does not establish. We give particular weight to results that conflict, to effect sizes measured in the wrong species, and to claims that circulate without a same-condition comparison behind them.Keywords
All Related Versions
This publication has 100 references indexed in Scilit:
- Pseudouridine RNA avoids immune detection through impaired endolysosomal processing and TLR engagementCell, 2025
- The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold CaseJournal of Pharmaceutical Sciences, 2022
- Circular RNA vaccines against SARS-CoV-2 and emerging variantsCell, 2022
- Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialeClinicalMedicine, 2022
- The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatoryiScience, 2021
- Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responsesImmunity, 2021
- Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message acrossAdvanced Drug Delivery Reviews, 2021
- Structured elements drive extensive circular RNA translationMolecular Cell, 2021
- mRNA vaccines manufacturing: Challenges and bottlenecksVaccine, 2021
- Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNAMolecular Therapy, 2021